{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-277631","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2026-06-22T20:52:39+00:00","discovered_at":"2026-06-22T20:53:00.099861+00:00","generated_at":"2026-06-22T20:53:10.459831+00:00","sec_items":["5.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CytomX shareholders approve charter amendment to double authorized common stock and equity plan increases","bullets":["Charter Amendment increased authorized common stock from 300M to 600M shares, effective June 22, 2026.","2015 Plan Amendment adds 6.5M shares to equity incentive plan; ESPP Amendment adds 1M shares.","Directors Matthew P. Young and Elaine V. Jones re-elected to Class II until 2029 Annual Meeting.","Advisory vote on executive compensation passed (147.1M for, 1.7M against); company will hold Say-on-Pay annually.","Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 183M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-277631","json":"https://secwatch.observer/filing/0001193125-26-277631.json","markdown":"https://secwatch.observer/filing/0001193125-26-277631.md","text":"https://secwatch.observer/filing/0001193125-26-277631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/d154321d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:53:10.459831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5598ecd0acd3a59ab5f0d1a4d3bdcf7039c1f635","claim":"CytomX Therapeutics, Inc.: Increased authorized shares of common stock from 300,000,000 to 600,000,000 (effective 2026-06-22).","evidence_excerpt":"On June 22, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 300,000,000 to 600,000,000 shares (the “Charter Amendment”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-22"}],"fact_type":"governance_change"},{"claim_id":"4d8511d76056e22c5efef8a7fcddc8041a36989c","claim":"CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 7. The non-binding, advisory vote regarding the frequency of future advisory votes by stockholders on the compensation of the Company’s named executive officers: 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 145,004,404 1,298,607 2,352,377 349,574 34,599,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"7d16e12d8dce5899e6db38ac84a2ef20d0c72359","claim":"CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the 2015 Plan at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 4. The Company’s stockholders approved an amendment to the 2015 Plan, as described in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,079,951 1,745,001 180,010 34,599,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"80688ff7db8fa82e30b69012fb15e18d1085db6b","claim":"CytomX Therapeutics, Inc. shareholders approved Election of Class II director nominees to the Board to hold office until the 2029 Annual Meeting at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 1. The Company’s stockholders elected the Class II director nominees below to the Board to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or the earlier of their death, resignation or removal. NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Matthew P. Young 146,742,827 2,062,471 199,664 34,599,122 Elaine V. Jones Ph.D. 131,377,301 17,428,951 198,710 34,599,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"ada1ec3018a278ea4824677d5eb53067ece17ef0","claim":"CytomX Therapeutics, Inc. shareholders approved Non-binding advisory vote on the compensation of the named executive officers (Say-on-Pay) at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 6. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,127,715 1,722,679 154,568 34,599,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"bc474c6f5af4b62c0ba089fe43babc430e539d77","claim":"CytomX Therapeutics, Inc. shareholders approved Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN 182,976,052 382,681 245,351","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"e8f8e73ca491d45f93243124836bd1d1cffd83ab","claim":"CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the Amended and Restated Employee Stock Purchase Plan at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 5. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 147,375,197 1,468,576 161,189 34,599,122","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"faa121ba57a424d10eb0069b05258b7dc2829ac1","claim":"CytomX Therapeutics, Inc. shareholders approved Approval of an amendment to the Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 600,000,000 at the 2026-06-17 meeting.","evidence_excerpt":"Proposal 3. The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares. FOR AGAINST ABSTAIN 178,362,995 4,771,689 469,400","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526277631/0001193125-26-277631-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}